These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9146849)

  • 1. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics.
    Rydberg T; Jönsson A; Karlsson MO; Melander A
    Br J Clin Pharmacol; 1997 Apr; 43(4):373-81. PubMed ID: 9146849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.
    Jönsson A; Rydberg T; Sterner G; Melander A
    Eur J Clin Pharmacol; 1998 Feb; 53(6):429-35. PubMed ID: 9551701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.
    Rydberg T; Jönsson A; Røder M; Melander A
    Diabetes Care; 1994 Sep; 17(9):1026-30. PubMed ID: 7988301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the kinetics of glyburide and its active metabolites in humans.
    Rydberg T; Jönsson A; Melander A
    J Clin Pharm Ther; 1995 Oct; 20(5):283-95. PubMed ID: 8576296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes.
    Jönsson A; Chan JC; Rydberg T; Vaaler S; Hallengren B; Cockram CS; Critchley JA; Melander A
    Eur J Clin Pharmacol; 2000 Jan; 55(10):721-7. PubMed ID: 10663449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes.
    Jönsson A; Hallengren B; Rydberg T; Melander A
    Diabetes Obes Metab; 2001 Dec; 3(6):403-9. PubMed ID: 11903411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.
    Bouazza N; Djerada Z; Gozalo C; Busiah K; Beltrand J; Berdugo M; Urien S; Treluyer JM; Polak M
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1373-1379. PubMed ID: 27561267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.
    Choy S; Hénin E; van der Walt JS; Kjellsson MC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):1-10. PubMed ID: 23179858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication.
    Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT
    Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects.
    Boni JP; Cevallos WH; DeCleene S; Korth-Bradley JM
    Pharmacotherapy; 1997; 17(4):783-90. PubMed ID: 9250558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.
    Ampudia-Blasco FJ; Heinemann L; Bender R; Schmidt A; Heise T; Berger M; Starke AA
    Diabetologia; 1994 Jul; 37(7):703-7. PubMed ID: 7958542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans.
    Yun HY; Park HC; Kang W; Kwon KI
    J Clin Pharm Ther; 2006 Oct; 31(5):469-76. PubMed ID: 16958825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Jun; 69(6):400-6. PubMed ID: 11406737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
    Kleist P; Ehrlich A; Suzuki Y; Timmer W; Wetzelsberger N; Lücker PW; Fuder H
    Eur J Clin Pharmacol; 1997; 53(2):149-52. PubMed ID: 9403288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of stress on the pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats.
    Abd Elaziz MA; Al-Dhawailie AA; Tekle A
    Eur J Drug Metab Pharmacokinet; 1998; 23(3):371-6. PubMed ID: 9842979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.